Adrenoceptor agonists and antagonists and risk of Parkinson's disease

Microstimulation of the human dopaminergic midbrain enhances outcome-related happiness and reduces loss seeking.

bioRxiv : the preprint server for biology·2026

Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease.

JAMA neurology·2025

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

NPJ Parkinson's disease·2025

Adrenergic blockers, statins, and non-steroidal anti-inflammatory drugs are associated with later age at onset in Parkinson's disease.

Journal of neurology·2025

Accelerating Parkinson's Disease drug development with federated learning approaches.

NPJ Parkinson's disease·2024

Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.

Nature medicine·2024

Serum Metabolomic Profiles Unveil Biomarkers and Core Metabolic Pathways in Multiple System Atrophy Patients.

Movement disorders : official journal of the Movement Disorder Society·2026

SLC7A6OS Founder Mutation: A Rare Cause of Progressive Myoclonus Epilepsy Dated to 1100 Years Ago.

Movement disorders : official journal of the Movement Disorder Society·2026

Efficacy and Safety of DL-3-n-Butylphthalide in Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026

A De Novo 16p13.3 Triplication Underlying Early-Onset Complex Neurodegeneration.

Movement disorders : official journal of the Movement Disorder Society·2026

Novel and Emerging Therapies for Childhood-Onset Movement Disorders.

Movement disorders : official journal of the Movement Disorder Society·2026

Selectivity Filter KCND3 Variant Causes Spinocerebellar Ataxia 19/22 and KV4.3 Functional Loss.

Movement disorders : official journal of the Movement Disorder Society·2026

SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes.

Frontiers in endocrinology·2026

A PBPK-VBE approach for bioequivalence extrapolation of senaparib capsule strengths in the context of nonlinear pharmacokinetics: bridging from the clinical starting dose to the linear pharmacokinetic range.

Frontiers in pharmacology·2026

Pre-Ramadan time-below-range stratifies the simulated pump basal-rate dose-response during Ramadan fasting: a five-policy paired virtual-patient study.

Frontiers in endocrinology·2026

Operationalization of the African Medicines Agency: Retrospective evaluation of the continental centralized pilot procedure timelines to recommendation and national registrations.

British journal of clinical pharmacology·2026

Symptom-based classification of Parkinson's disease using retrospective electronic medical records: A STROBE-compliant cross-sectional study.

Medicine·2026

Gastrointestinal and skin safety evaluation of pirfenidone versus nintedanib: an analysis of real-world pharmacovigilance and randomized controlled trials.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Related Experiment Videos

Adrenoceptor agonists and antagonists and risk of Parkinson's disease

Related Concept Videos

Microstimulation of the human dopaminergic midbrain enhances outcome-related happiness and reduces loss seeking.

Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease.

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Adrenergic blockers, statins, and non-steroidal anti-inflammatory drugs are associated with later age at onset in Parkinson's disease.

Accelerating Parkinson's Disease drug development with federated learning approaches.

Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.

Serum Metabolomic Profiles Unveil Biomarkers and Core Metabolic Pathways in Multiple System Atrophy Patients.

SLC7A6OS Founder Mutation: A Rare Cause of Progressive Myoclonus Epilepsy Dated to 1100 Years Ago.

Efficacy and Safety of DL-3-n-Butylphthalide in Spinocerebellar Ataxia Type 3.

A De Novo 16p13.3 Triplication Underlying Early-Onset Complex Neurodegeneration.

Novel and Emerging Therapies for Childhood-Onset Movement Disorders.

Selectivity Filter KCND3 Variant Causes Spinocerebellar Ataxia 19/22 and KV4.3 Functional Loss.

SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes.

A PBPK-VBE approach for bioequivalence extrapolation of senaparib capsule strengths in the context of nonlinear pharmacokinetics: bridging from the clinical starting dose to the linear pharmacokinetic range.

Pre-Ramadan time-below-range stratifies the simulated pump basal-rate dose-response during Ramadan fasting: a five-policy paired virtual-patient study.

Operationalization of the African Medicines Agency: Retrospective evaluation of the continental centralized pilot procedure timelines to recommendation and national registrations.

Symptom-based classification of Parkinson's disease using retrospective electronic medical records: A STROBE-compliant cross-sectional study.

Gastrointestinal and skin safety evaluation of pirfenidone versus nintedanib: an analysis of real-world pharmacovigilance and randomized controlled trials.

Related Experiment Videos

Adrenoceptor agonists and antagonists and risk of Parkinson's disease

Related Concept Videos

Related Articles